https://www.databridgemarketresearch.com/reports/global-antibody-drug-conjugates-contract-manufacturing-market Market Forecast for Antibody Drug Conjugates Contract Manufacturing The Antibody Drug Conjugates contract manufacturing market is entering a "Golden Age." With the global cancer burden rising and a transition toward personalized medicine, the demand for specialized outsourced manufacturing is outstripping current capacity. By 2026, as the market scales toward USD 12 billion, the focus will shift from simple production to technological superiority in linker stability and high-yield bioprocesses. The strategic moves by players like Lonza and Samsung Biologics to integrate the entire supply chain suggest that the future of ADC success lies in seamless, end-to-end manufacturing partnerships.